A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).

Trial Profile

A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs AZD 1208 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Apr 2016 Pooled analysis of 2 studies, including 32 patients from this trial and 35 patients from another study [see CTP 700216938] were presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 23 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 24 Apr 2014 Planned End Date changed from 1 Aug 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top